Conivaptan (Hydrochloride) is a non-peptide antagonist of vasopressin receptor, with Ki values of 0.48 and 3.04 nM for rat liver V1A receptor and rat kidney V2 receptor respectively. At 4 weeks after coronary occlusion, conivaptan (0.03, 0.1 and 0.3 mg/kg i.v.) dose-dependently increased urine volume and reduced urine osmolality in both myocardial infarction and sham-operated rats. Conivaptan (0.3 mg/kg i.v.) significantly reduced right ventricular systolic pressure, left ventricular end-diastolic pressure, lung/body weight and right atrial pressure in myocardial infarction rats. Moreover, conivaptan (0.3 mg/kg i.v.) significantly increased dP/dt(max)/left ventricular pressure[3]. Conivaptan produces an acute increase in urine volume (UV), a reduction in osmolality (UOsm) and, at the end of the investigation, cirrhotic rats receiving the V(1a)/V(2)-AVP receptor antagonist does not show hyponatremia or hypoosmolality. Conivaptan also normalizes U(Na)V without affecting creatinine clearance and arterial pressure[4]. Conivaptan (0.1 mg/kg, i.v.) improves cardiac function, as evidenced by significant increases in left ventricular dP/dtmax, cardiac output and stroke volume, and reduces preload and afterload, as evidenced by significant decreases in left ventricular end-diastolic pressure and total peripheral vascular resistance in dogs with congestive heart failure[5].
Right Heart Failure
... 展开 >> Pulmonary Hypertension 收起 <<
Not Applicable
Withdrawn(Only 1 patient recru... 展开 >>ited, and he withdrew) 收起 <<
-
United States, Colorado
... 展开 >>
University of Colorado at Denver and Health Sciences Center General Clinical Research Center
Denver, Colorado, United States, 80262 收起 <<
Right Heart Failure
... 展开 >> Pulmonary Hypertension 收起 <<
Not Applicable
Withdrawn(Only 1 patient recru... 展开 >>ited, and he withdrew) 收起 <<
-
United States, Colorado
... 展开 >>
University of Colorado at Denver and Health Sciences Center General Clinical Research Center
Denver, Colorado, United States, 80262 收起 <<
United States, Arizona
... 展开 >>
Tuscon, Arizona, United States, 85723
United States, Colorado
Denver, Colorado, United States, 80262
United States, District of Columbia
Washington, District of Columbia, United States, 20007
United States, Georgia
Augusta, Georgia, United States, 30901
United States, Michigan
Petoskey, Michigan, United States, 49700
United States, Ohio
Cincinnati, Ohio, United States, 45219
United States, South Carolina
Columbia, South Carolina, United States, 29209
Israel
Afula, Israel
Ashkelon, Israel
Hadera, Israel
2 Sites
Haifa, Israel
Holon, Israel
2 Sites
Jerusalem, Israel
Nahariya, Israel
Rechovot, Israel
2 Sites
Safed, Israel
Tel-Aviv, Israel
Zerifin, Israel
South Africa
Amanzimototi, South Africa
Bellville, South Africa
Bloemfontein, South Africa
2 Sites
Durban, South Africa
4 Sites
Johannesburg, South Africa
Krugersdorp, South Africa
Lyttelton, South Africa
Pretoria, South Africa
Somerset West, South Africa
Soweto, South Africa 收起 <<
Terminated(The clinical study ... 展开 >>has been terminated based on difficulties to enroll eligible subjects per protocol inclusion and exclusion criteria.) 收起 <<
-
India
... 展开 >>
Hyderabaad, India, 500063
Karnal, India, 132001
New Delhi, India, 110025
New Delhi, India, 110060 收起 <<
United States, Minnesota
... 展开 >>
Hennepin county Medical Center
Not yet recruiting
Minneapolis, Minnesota, United States, 55404
Principal Investigator: Steven R Goldsmith, MD 收起 <<
Terminated(Enrollment goals we... 展开 >>re not met.) 收起 <<
-
United States, New York
... 展开 >>
Children's Hospital of New York - Presbyterian
New York, New York, United States, 10032
Colombia
Fundación Cardioinfantil - Instituto Cardiológico
Bogota, Colombia
Fundación Valle del Lili
Cali, Valle, Colombia 收起 <<
United States, California
... 展开 >>
Advanced Clinical Research Institute
Anaheim, California, United States, 92801
United States, Colorado
DaVita Clinical Research
Lakewood, Colorado, United States, 80228
United States, Florida
Orlando Clinical Research
Orlando, Florida, United States, 32809 收起 <<
Terminated(The clinical study ... 展开 >>has been terminated based on difficulties to enroll eligible subjects per protocol inclusion and exclusion criteria.) 收起 <<
搜索
